BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Genetown

  Advanced Aesthetic Technologies Announces New Financing on Netcapital Private Securities Platform

  AAT to raise equity financing via Netcapital funding portal

  November 14, 2018

   · 

  3 min read
• FDA

  Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache

  Lilly also plans to submit a supplemental Biologics License Application (sBLA) to the FDA for Emgality for the preventive treatment of episodic cluster headache by the end of the year, reflecting its commitment to disabling headache disorders

  November 14, 2018

   · 

  10 min read
• Drug Development

  Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

  With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients

  November 14, 2018

   · 

  27 min read
• Business

  Canopy Growth Corporation Reports Second Quarter Fiscal 2019 Financial Results

  The Company secured a strategic $5 billion investment from Fortune 500 beverage leader Constellation Brands

  November 14, 2018

   · 

  32 min read
• Pharm Country

  Averitas Pharma Commercializes Qutenza® in the US

  Averitas Pharma, a recently acquired Grünenthal Group company, announced that it has taken over the US commercialization of Qutenza® (capsaicin) 8% patch on October 30, after the acquisition of the product by Grünenthal on the same day.

  November 14, 2018

   · 

  4 min read
• Business

  Tikcro Technologies Reports Third Quarter 2018 Results

  Continued Advancement of a New CTLA-4 Antibody with Superior Pre-clinical Qualities

  November 14, 2018

   · 

  3 min read
• Business

  Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results

  Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease

  November 14, 2018

   · 

  11 min read
• Business

  Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

  Precision BioSciences gains rights to MaxCyte’s cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision’s ARCUS® genome-editing technology

  November 14, 2018

   · 

  3 min read
• Business

  Vineti and Quick Specialized Healthcare Logistics Partner to Share Industry Expertise That Helps Strengthen Cell and Gene Therapy Supply Chains

  A new tip sheet from industry experts at Vineti and Quick provides time-proven best practices from cell and gene therapy veterans to synchronize personalized therapy supply chains and help bring more transformative treatments to more patients

  November 14, 2018

   · 

  4 min read
• Business

  Supreme Cannabis Announces Record Revenues For Q1 2019

  Q1 2019 revenue for the Company was $5.14 million, a 229% increase from Q1 2018

  November 14, 2018

   · 

  6 min read